Loading...
Loading...
Shares of Hologic, Inc
HOLX have moved higher 1.7 percent to $21.38 in Monday's trading following some bullish comments from Piper Jaffray.
Analyst William Quirk believes Hologic could see ~$27.9 million in annual revenue from Grifols' seven year contract with the Japanese Green Cross to screen blood supply using Procleix.
The deal between Grifols and the Japanese Green Cross is valued at $375 million, meaning $195 million in revenue for Hologic at the current revenue split agreement.
Quirk maintained a Neutral rating on the stock.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in